budesonide + formoterol + doxophylline

This combination therapy consists of the inhaled corticosteroid budesonide, the long-acting beta-2 agonist (LABA) formoterol, and the oral methylxanthine derivative doxophylline. It was evaluated in a clinical trial conducted by the Government Medical College, Bhavnagar, as a treatment regimen for patients with moderate to severe persistent bronchial asthma who were poorly controlled on standard therapy. Budesonide acts as an anti-inflammatory agent by activating glucocorticoid receptors, while formoterol provides prolonged bronchodilation through beta-2 adrenergic receptor stimulation. Doxophylline, a newer-generation methylxanthine, acts primarily as a phosphodiesterase inhibitor to provide additional bronchodilation and anti-inflammatory effects with an improved safety profile compared to theophylline, specifically exhibiting lower affinity for adenosine receptors.

Other names

budesonide/formoterol plus doxophyllineinhaled budesonide and formoterol plus oral doxophylline